Swixx BioPharma GEOGRAPHIC AND THERAPEUTIC FOCUS While today Swixx BioPharma is primarily focused on the CEE region, Swixx BioPharma anticipates to further expand to Russia / CIS countries, and later possibly to Western Europe, Middle East or Africa. That said, Swixx BioPharma’s focus is in the following therapeutic areas: Modern, high tech, professionally-positioned products with a compelling medical proposition (evidence based medicine / significant clinical impact), especially in oncology/hematology, nephrology, transplantation medicines, GI and other specialty. Rare disease / orphan medicines - new, dedicated business unit formed as of December, 2018 OTCs / Open Market preferably established brands or products with Unique Selling Propositions Out of pocket / largely non-reimbursed products, in areas of critical unmet needs Products with rapid regulatory pathways: Medical Devices / Food Supplements / Cosmetics and products with existing registrations Selective Purchase of existing brands or platforms that carefully complement our partners portfolios
Swixx BioPharma is focused on CEE region Albania Bosnia and Herzegovina Belarus Bulgaria Croatia Czech Republic Estonia Greece Hungary Kazakhstan Kosovo Latvia Lithuania Moldova Montenegro North Macedonia Poland Romania Russia Serbia Slovakia Slovenia Uzbekistan
This region comprise 275 million people and a pharmaceutical market of 50+ billion Euros. Their economies currently are amongst the least developed in Europe, but they show considerable promise and boast well-educated and cultured people. Many western healthcare companies chose not to enter these markets, but nonetheless wish to have their products present and represented by a professional, compliant and competent regional partner. Swixx BioPharma aims to fill this need and to bring modern medicines to the people of the region.
A Swiss-based Pharmaceutical Company
© 2019 Swixx Biopharma SA. All rights reserved. Terms of Use. Privacy Policy. PV Data Privacy. Cookie Policy.